BioLife Solutions reported second-quarter 2026 revenue of $28.5 million, up 21% from a year earlier, and GAAP net income of $45.1 million, which includes a $42.4 million non-cash income tax benefit from the release of a valuation allowance. The company also disclosed a July 21, 2026 agreement under which Repligen will acquire BioLife for a total enterprise value of about $1.5 billion, after which BioLife will no longer be publicly traded, so shareholders' outcome depends on that deal closing.
Q2 2026 revenue was $28.5 million, up $5.0 million or 21% from $23.4 million in Q2 2025 and up 4% from Q1 2026.
GAAP net income was $45.1 million, or $0.92 per basic share, including the $42.4 million tax benefit; adjusted net income was $4.2 million.
GAAP gross margin was 64% versus 65% a year earlier; adjusted EBITDA was $7.4 million, or 26% of revenue.
Repligen will pay $11.25 in cash and 0.1442 Repligen shares per BioLife share; closing is expected in Q4 2026, subject to stockholder and regulatory approvals.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
From BioLife Solutions, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$96.21M
+28.9%
$-0.10
—
-4.8%
FY2024
$74.65M
+9.7%
$-0.44
—
-27.0%
FY2023
$68.02M
-10.8%
$-1.55
—
-100.0%
FY2022
$76.24M
-36.0%
$-3.25
—
-183.4%
FY2021
$119.16M
+147.8%
$-0.23
—
-7.5%
Frequently asked questions
When is BioLife Solutions's next earnings date?
BioLife Solutions has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did BioLife Solutions earn last quarter?
For the quarter ended Jun 2026, BioLife Solutions reported diluted EPS of $0.91 on revenue of $28.47M (+21.5%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.